简介:PURPOSE:ResistancetotemozolomidechemotherapyispartlymediatedbyO^6-methylguanine-DNAmethlytransferase(MGMT).ProtractedtreatmentwithtemozolomidepotentiallyovercomesMGMTresistanceandimprovesoutcome.WeconductedaphaseIIstudyofprotracteddailytemozolomideinadultswithlow-gradegliomas.EXPERIMENTALDESIGN:PatientswithnewlydiagnosedoligodendrogliomaoroligoastrocytomawithaMIB-1indexof〉5%orrecurrentlow-gradegliomasreceivedtemozolomide(75mg/m^2/dayin11-weekcyclesof7weekson/4weeksoff).Treatmentcontinuedforatotalofsixcyclesoruntiltumorprogressionorunacceptabletoxicity.Primaryendpointwasbestoverallresponserate;secondaryendpointswereprogression-freesurvival,overallsurvival,andtoxicity.